Psychomotor and neurofunctional aspects after Covid-19

Supplementary Tables and Figures

Supplementary Table 1. Date of diagnoses in Phase 2. Date (month/year) that post-Covid-19 subjects of different age groups evaluated in Phase 2 were diagnosed with Covid-19 (n=30)

Date of diagnoses	age groups (years old)		
	18-30	31-45	46-64
April/2020	0	1	0
May/2020	1	1	0
June/2020	0	3	1
August/2020	0	1	1
September/2020	0	0	1
October/2020	0	0	1
November/2020	1	1	2
December/2020	2	0	0
January/2021	1	1	2
February/2021	0	2	0
March/2021	1	0	1
May/2021	0	2	0
June/2021	0	0	1
August/2021	0	1	1
Total	6	13	11

Supplementary Table 2. Symptoms in Phase 1. Symptoms reported during the course of Covid-19 (evaluated in Phase 1, number, No., percentage, %, n=184)

Symptoms	No.	%
Loss of smell and/or taste	126	68.48
Headache	123	66.85
Fatigue	112	60.87
Body pain	111	60.33
Fever	86	46.74
Cough	80	43.48
Coryza	64	34.78
Diarrhea	64	34.78
Sore throat	62	33.70
Dizziness	52	28.26
Difficulty breathing	50	27.17
Chest pain/pressure	45	24.46
Nausea and/or vomiting	43	23.37
Alteration of consciousness	20	10.87
Others	19	10.33
Ataxia	8	4.35
Asymptomatic	6	3.26
Speech impairment	2	1.09
Convulsion	0	0.00
Total of subjects	184	100

Supplementary Table 3. Symptoms in Phase 2. Symptoms reported during the course of Covid-19 by different age groups (evaluated in Phase 2, number, No., percentage, %, n=30)

Symptoms	No. 18-30 years old	% 18-30 years old	No. 31-45 years old	% 31-45 years old	No. 46-64 years old	% 46-64 years old	Total	%
Fever	3	7	7	8	7	8	17	8
Fatigue	5	12	9	10	9	10	23	10
Body pain	4	9	10	11	10	11	24	11
Headache	5	12	12	13	12	13	29	13
Loss of smell and/or taste	6	14	10	11	10	11	26	12
Nausea and/or vomiting	2	5	2	2	2	2	6	3
Diarrhea	3	7	7	8	7	8	17	8
Difficulty breathing	1	2	3	3	3	3	7	3
Chest pain/pressure	3	7	4	4	4	4	11	5
Dizziness	2	5	5	5	5	5	12	5
Coryza	2	5	5	5	5	5	12	5
Cough	2	5	5	5	5	5	12	5
Sore throat	4	9	5	5	5	5	14	6
Alteration of consciousness	1	2	5	5	5	5	11	5
Ataxia	0	0	2	2	2	2	4	2
Total	43	100	91	100	91	100	225	100

Supplementary Table 4. Pre-existing diseases in Phase 1. Occurrence of pre-existing diseases reported by subjects affected by post-Covid-19 (evaluated in Phase 1, number, No., percentage, %, n=184)

Pre-existing diseases	No.	%
None	116	63.04
High blood pressure	26	14.13
Asthma or bronchitis	15	8.15
Others	13	7.07
Diabetes	8	4.35
Heart diseases	6	3.26
Total	184	100

Supplementary Table 5. Pre-existing diseases in Phase 2. Occurrence of pre-existing diseases reported by subjects of different age groups affected by post-Covid-19 and controls (evaluated in Phase 2, percentage, %, n=30)

Pre-existing diseases	18-30 years old		31-45 years old		46-64 years old		Total	%	
	control	post-Covid-19	control	post-Covid-19	control	post-Covid-19		control	post-Covid-19
None	5	5	10	11	9	4	44	80.0	66.7
Asthma or bronchitis	1	1	1	1	1	2	7	10.0	13.3
High pressure	0	0	2	0	0	3	5	6.7	10.0
Hyperthyroidism	0	0	0	1	0	0	1	0.0	3.3
Fibromyalgia	0	0	0	0	0	1	1	0.0	3.3
Obesity	0	0	0	0	1	0	1	3.3	0
Gastritis	0	0	0	0	0	1	1	0.0	3.3

Supplementary Table 6. Medical care. Medical care adopted for the subjects of different age groups affected by Covid-19 (evaluated in Phase 2, number, No., percentage, %, n=30)

Medical care	18-30 years old			31-45 years old			46-64 years old		
	No.	%	% (Total)	No.	%	% (Total)	No.	%	% (Total)
Home isolation	2	33	7	7	54	23	5	45	17
Hospital emergency care and home care	4	67	13	6	46	20	5	45	17
Hospital admission without mechanical ventilation	0	0	0	0	0	0	0	0	0
Hospital admission and mechanical ventilation	0	0	0	0	0	0	0	0	0
Intensive care unit without mechanical ventilation/intubation	0	0	0	0	0	0	1	9	3
Intensive care unit and mechanical ventilation/intubation	0	0	0	0	0	0	0	0	0
Total	6	100	20	13	100	43	11	100	37

Supplementary Figure 1. Date of diagnoses in Phase 1. Date (month/year) that post-Covid-19 subjects evaluated in Phase 1 were diagnosed with Covid-19 (n=184)

Supplementary Figure 2. Blood type in Phase 2. Blood type of post-Covid-19 and control subjects evaluated in Phase 2 and values of the Brazilian population (percentage, %, n=30/group). # data from Hemocentro (2018)